A screening assay in the search of an alpha-synuclein PET radioligand
Abstract
The accumulation of aggregated α-synuclein (α-Syn) in multiple brain regions is a neuropathological hallmark of synucleinopathies like Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. A pre-mortem diagnosis tool would improve early diagnosis, monitor disease progression and therapeutic efficacy. While suitable amyloid-β (Aβ) PET radiotracers have been developed, no selective α-Syn PET ligand has been identified to date. One PET tracer, BF227, labelled with carbon-11 or fluor-18, has demonstrated interesting binding properties towards α-Syn fibrils in vitro (1) and α-Syn glial inclusions in MSA patients (2).
Origin : Files produced by the author(s)